PMID- 23123583
OWN - NLM
STAT- MEDLINE
DCOM- 20131112
LR  - 20151119
IS  - 1827-1898 (Electronic)
IS  - 0031-0808 (Linking)
VI  - 54
IP  - 4
DP  - 2012 Dec
TI  - The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in 
      pathology.
PG  - 305-12
AB  - The immunoglobulin E (IgE) are a key factor in the pathophysiology of allergic 
      diseases and the important therapeutic role of an anti-IgE antibody was long 
      envisioned. It took time and efforts to solve the safety problems related to the 
      anaphylactogen capacity of anti-IgE, finally crowned by the introduction of the 
      humanized, monoclonal anti-IgE antibody omalizumab. Currently, omalizumab is 
      indicated, based on clear evidence of efficacy, only in severe allergic asthma 
      not controlled by conventional treatment. However, a continuously increasing 
      amount of literature shows that omalizumab is efficacious in a number of 
      disorders concerning the upper and lower airway and the skin, and, most 
      importantly, in anaphylaxis. The latter application was demonstrated successful 
      in placebo-controlled trials and warrants for a new, life-saving, indication for 
      omalizumab. Also, the systemic reactions precluding the performance of allergen 
      immunotherapy, especially concerning Hymenoptera venom, were prevented by 
      omalizumab treatment. The most surprising success of omalizumab regards clinical 
      conditions thus far considered unrelated to IgE antibodies. This is true for 
      intrinsic asthma and for idiopathic urticaria (demonstrated by a 
      placebo-controlled trial), and angioedema, suggesting in these condition a 
      pathophysiologic role of IgE. These observations support a off-label use of 
      omalizumab in patients suffering from IgE-related pathologies other than asthma 
      who are at risk of fatal events or are uncontrolled by the optimal standard 
      treatment.
FAU - Mauro, M
AU  - Mauro M
AD  - Allergy Unit, Sant'Anna Hospital, Como, Italy.
FAU - Incorvaia, C
AU  - Incorvaia C
FAU - Formigoni, C
AU  - Formigoni C
FAU - Elia, R
AU  - Elia R
FAU - Russello, M
AU  - Russello M
FAU - Pellegrino, D
AU  - Pellegrino D
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Italy
TA  - Panminerva Med
JT  - Panminerva medica
JID - 0421110
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Humans
MH  - Hypersensitivity/blood/*drug therapy/immunology
MH  - Immunoglobulin E/blood/*immunology
MH  - Off-Label Use
MH  - Omalizumab
MH  - Practice Guidelines as Topic
MH  - Signal Transduction/drug effects
EDAT- 2012/11/06 06:00
MHDA- 2013/11/13 06:00
CRDT- 2012/11/06 06:00
PHST- 2012/11/06 06:00 [entrez]
PHST- 2012/11/06 06:00 [pubmed]
PHST- 2013/11/13 06:00 [medline]
AID - R41122702 [pii]
PST - ppublish
SO  - Panminerva Med. 2012 Dec;54(4):305-12.